创新药先锋荣昌生物的烦恼:刚从巨亏熬到预计减亏3%,核心技术人员“药审大佬”却离职了

华夏时报
20 Feb

作为曾经国产“ADC(抗体药物偶联物)赛道”的领头羊,荣昌生物如今却是危机重重。  据荣昌生物近日披露的业绩预告,公司预计2024年度营业收入约人民币17.15亿元,同比增加约58%;预计当期归母净亏损约14.7亿元,同比亏损减少约3%。公司的两大单品泰它西普和维迪西妥单抗销售收入快速增长,产品毛利率持续增长,销售费用率明显下降。  虽然减亏幅度不大,但对于已经连续亏损两年的荣昌生物而言也算是个...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10